|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.2316 - 0.2513|
|52-week range||0.2316 - 0.2513|
|Beta (5Y monthly)||1.29|
|PE ratio (TTM)||N/A|
|Earnings date||22 Mar 2022 - 28 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
It's not possible to invest over long periods without making some bad investments. But really bad investments should be...
Abeona Therapeutics (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front